In CLL, experiments show the presence of NRF2 signaling and suggest that altered NRF2 responses may contribute to the observed selective cytotoxicity of electrophilic compounds in this disease [49]. The gene discussed is NFE2L2; the disease is B-cell chronic lymphocytic leukemia.